Revenue from Contract with Customer, Excluding Assessed Tax of Spero Therapeutics, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Spero Therapeutics, Inc. quarterly and annual Revenue from Contract with Customer, Excluding Assessed Tax in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • Spero Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 30 Sep 2025 was $0, a 100% decline year-over-year.
  • Spero Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending 30 Sep 2025 was $64,000, a 88% decline year-over-year.
  • Spero Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2024 was $371,000, a 60% decline from 2023.
  • Spero Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $933,000, a 63% decline from 2022.
  • Spero Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $2,503,000, a 18% decline from 2021.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)

Spero Therapeutics, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $64,000 $0 -$65,000 -100% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $129,000 $0 -$114,000 -100% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $243,000 $12,000 -$128,000 -91% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $371,000 $52,000 -$171,000 -77% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $542,000 $65,000 -$153,000 -70% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $695,000 $114,000 -$155,000 -58% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $850,000 $140,000 -$83,000 -37% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $933,000 $223,000 -$55,000 -20% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $988,000 $218,000 -$864,000 -80% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $1,852,000 $269,000 -$627,000 -70% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 $2,479,000 $223,000 -$24,000 -9.7% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $2,503,000 $278,000 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
Q3 2022 $1,082,000 +$374,000 +53% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $896,000 -$1,210,000 -57% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $247,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q3 2021 $708,000 +$670,000 +1763% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $2,106,000 +$2,055,000 +4029% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q4 2020 $258,000 $0 -$696,000 -100% 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q3 2020 $954,000 $38,000 -$134,000 -78% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $1,088,000 $51,000 -$16,000 -24% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $1,104,000 $169,000 -$3,638,000 -96% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $4,742,000 $696,000 01 Oct 2019 31 Dec 2019 10-K 16 Mar 2020 2019 FY
Q3 2019 $172,000 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $67,000 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $3,807,000 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1

Spero Therapeutics, Inc. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $371,000 -$562,000 -60% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $933,000 -$1,570,000 -63% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $2,503,000 -$567,000 -18% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
2021 $3,070,000 +$2,812,000 +1090% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $258,000 -$4,484,000 -95% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
2019 $4,742,000 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.